Hospital
Martha's Vineyard Hospital, INC.
Martha's Vineyard Hospital, INC. was paid $50.35M by Medicaid between Jan 2018 and Dec 2024, across 304 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 33% of everything it billed.
33Billing provider infoMARTHA'S VINEYARD HOSPITAL, INC.
OAK BLUFFS, MA 02557
OAK BLUFFS, MA 02557
33aNPI1134206386assigned 11/01/2006
33bProvider typeCritical Access Hospital
28Total paid$50.35M
24GClaims548,261
24DCodes billed304
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Massachusetts
Rank by total paid#1 of 5
Median peer was paid$7.11M
This provider vs. median7.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 66,102 | $6.55M | |
| 2019 | 75,028 | $8.07M | |
| 2020 | 68,198 | $6.76M | |
| 2021 | 110,933 | $8.34M | |
| 2022 | 102,577 | $12.17M | |
| 2023 | 77,776 | $5.43M | |
| 2024incomplete | 47,647 | $3.04M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 33% | 51,754 | 41,436 | $16.61M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 20,747 | 18,463 | $5.86M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.2% | 4,460 | 3,887 | $4.13M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.3% | 14,899 | 13,311 | $3.70M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.1% | 15,317 | 4,522 | $2.08M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.7% | 7,071 | 5,580 | $1.36M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.0% | 4,751 | 4,092 | $1.02M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.7% | 4,137 | 4,126 | $833K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 2,498 | 1,897 | $764K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 1,903 | 1,803 | $749K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.5% | 3,251 | 3,223 | $747K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 2,692 | 2,454 | $731K |
292 more codes
| 99213 | Doctor's office visit, returning patient (routine) | 1.4% | 13,117 | $705K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.2% | 8,128 | $607K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.2% | 3,225 | $591K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 1,623 | $546K |
| 92552 | <1% | 1,703 | $436K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,401 | $432K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 2,163 | $411K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 8,414 | $409K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,125 | $386K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,525 | $358K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,751 | $304K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,330 | $243K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 763 | $218K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 754 | $210K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 582 | $201K |
| 90651 | <1% | 639 | $197K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,221 | $190K |
| 97161 | <1% | 1,400 | $181K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,637 | $180K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,202 | $172K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 967 | $170K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,955 | $166K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,535 | $162K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,385 | $156K |
| 76830 | Ultrasound, transvaginal | <1% | 681 | $153K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 7,791 | $151K |
| 59025 | Fetal non-stress test | <1% | 197 | $123K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,641 | $112K |
| 90715 | <1% | 1,779 | $96K | |
| 90686 | <1% | 4,640 | $95K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,012 | $94K |
| 86618 | <1% | 4,602 | $91K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,266 | $89K |
| 0002A | <1% | 2,622 | $87K | |
| 0001A | <1% | 2,708 | $84K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,533 | $83K |
| 99201 | <1% | 231 | $83K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 45 | $82K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,301 | $82K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,282 | $80K |
| J3490 | Unclassified drugs | <1% | 2,375 | $76K |
| 96127 | <1% | 1,390 | $70K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,487 | $68K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,658 | $66K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,471 | $65K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 841 | $64K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 370 | $64K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 206 | $60K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,533 | $59K |
| 87631 | <1% | 573 | $58K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,666 | $58K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 572 | $57K |
| G0378 | Hospital observation service, per hour | <1% | 476 | $57K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,225 | $54K |
| ATP15 | <1% | 7,488 | $51K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,083 | $51K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 87 | $49K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,752 | $44K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,171 | $44K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 17 | $43K |
| D1110 | Prophylaxis - adult | <1% | 1,623 | $41K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,697 | $36K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,429 | $34K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 6,414 | $31K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,197 | $31K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,608 | $29K |
| ATP14 | <1% | 4,888 | $28K | |
| ATP08 | <1% | 5,590 | $27K | |
| 0011A | <1% | 967 | $25K | |
| 0012A | <1% | 899 | $24K | |
| 84702 | <1% | 2,059 | $23K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,863 | $23K |
| 84484 | <1% | 2,827 | $23K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 154 | $22K |
| 90750 | <1% | 83 | $21K | |
| 73630 | <1% | 810 | $20K | |
| 85027 | <1% | 5,852 | $19K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 84 | $19K |
| 90461 | <1% | 2,726 | $19K | |
| 90620 | <1% | 89 | $18K | |
| 20610 | <1% | 51 | $18K | |
| 87800 | <1% | 602 | $18K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,358 | $18K |
| 0004A | <1% | 452 | $17K | |
| ATP17 | <1% | 2,483 | $17K | |
| 80050 | General health panel | <1% | 1,454 | $17K |
| 83690 | <1% | 3,742 | $17K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,957 | $17K |
| 73564 | <1% | 646 | $16K | |
| 86803 | <1% | 2,048 | $16K | |
| 83735 | <1% | 5,139 | $16K | |
| 86141 | <1% | 2,092 | $16K | |
| 76801 | <1% | 33 | $15K | |
| D9110 | <1% | 798 | $15K | |
| 81025 | <1% | 2,848 | $15K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 47 | $14K |
| 0124A | <1% | 357 | $14K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 677 | $14K |
| 88271 | <1% | 760 | $14K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 99 | $14K |
| 83605 | <1% | 2,348 | $13K | |
| 73030 | <1% | 499 | $13K | |
| 87400 | <1% | 1,290 | $13K | |
| 81001 | <1% | 6,319 | $12K | |
| 82728 | <1% | 1,818 | $12K | |
| D0120 | Dental checkup, returning patient | <1% | 974 | $12K |
| 76642 | <1% | 81 | $12K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 281 | $12K |
| 87490 | <1% | 780 | $12K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 850 | $12K |
| 83655 | <1% | 1,064 | $12K | |
| 82607 | <1% | 1,727 | $11K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 407 | $11K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 40 | $11K |
| 87077 | <1% | 2,363 | $11K | |
| 86617 | <1% | 1,077 | $11K | |
| 0064A | <1% | 257 | $11K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,698 | $11K |
| 84439 | <1% | 2,147 | $11K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 555 | $10K |
| 84153 | <1% | 1,179 | $10K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,223 | $10K |
| 87186 | <1% | 1,871 | $10K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 18 | $9K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $9K |
| 81003 | <1% | 5,986 | $9K | |
| ATP03 | <1% | 1,653 | $9K | |
| 80053 | Comprehensive metabolic panel | <1% | 10,360 | $8K |
| 97116 | <1% | 112 | $8K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 124 | $8K |
| 80076 | <1% | 9,024 | $7K | |
| 85610 | <1% | 4,209 | $7K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 850 | $7K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 415 | $7K |
| 73610 | <1% | 407 | $7K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 115 | $7K |
| 97162 | <1% | 52 | $6K | |
| 87040 | <1% | 709 | $6K | |
| D0274 | Bitewings - four radiographic images | <1% | 283 | $6K |
| 90670 | <1% | 1,846 | $6K | |
| 72100 | <1% | 145 | $6K | |
| 80061 | Lipid panel | <1% | 8,066 | $5K |
| 0054A | <1% | 206 | $5K | |
| 97165 | <1% | 25 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,628 | $5K |
| 71250 | <1% | 50 | $5K | |
| 0071A | <1% | 150 | $5K | |
| 83550 | <1% | 1,360 | $5K | |
| 90677 | <1% | 40 | $5K | |
| 86757 | <1% | 340 | $4K | |
| 83880 | <1% | 371 | $4K | |
| 73130 | <1% | 210 | $4K | |
| 90696 | <1% | 60 | $4K | |
| 85652 | <1% | 2,469 | $4K | |
| 83540 | <1% | 1,446 | $4K | |
| 93017 | <1% | 26 | $4K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 95 | $4K |
| 0072A | <1% | 77 | $4K | |
| 87506 | <1% | 29 | $3K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 425 | $3K |
| D0210 | Intraoral - complete series of radiographic images | <1% | 95 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,829 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,012 | $3K |
| 99443 | <1% | 483 | $3K | |
| 86668 | <1% | 307 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,100 | $3K |
| 85379 | <1% | 387 | $3K | |
| 76536 | <1% | 12 | $3K | |
| 86000 | <1% | 491 | $2K | |
| 86850 | <1% | 414 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 686 | $2K |
| 87420 | <1% | 213 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 496 | $2K |
| D2330 | <1% | 63 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 55 | $2K |
| 87207 | <1% | 464 | $2K | |
| 0134A | <1% | 45 | $2K | |
| 87481 | <1% | 95 | $2K | |
| 82043 | <1% | 823 | $2K | |
| 86592 | <1% | 590 | $2K | |
| 87070 | <1% | 283 | $2K | |
| 90732 | <1% | 42 | $2K | |
| 90662 | <1% | 148 | $1K | |
| 73502 | <1% | 13 | $1K | |
| 73110 | <1% | 99 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 588 | $1K |
| 87184 | <1% | 262 | $1K | |
| ATP16 | <1% | 189 | $1K | |
| D1206 | Topical application of fluoride varnish | <1% | 40 | $1K |
| 82746 | <1% | 173 | $1K | |
| 84403 | <1% | 86 | $1K | |
| 90656 | <1% | 46 | $1K | |
| 90734 | <1% | 475 | $894.38 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 276 | $874.57 |
| 86787 | <1% | 75 | $829.57 | |
| 90633 | <1% | 1,325 | $823.86 | |
| 87469 | <1% | 537 | $772.44 | |
| 80305 | <1% | 90 | $749.28 | |
| 86900 | <1% | 424 | $726.78 | |
| 87484 | <1% | 568 | $725.35 | |
| 73140 | <1% | 26 | $713.14 | |
| 86901 | <1% | 420 | $710.40 | |
| 90480 | <1% | 99 | $704.57 | |
| ATP11 | <1% | 109 | $688.06 | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 93 | $682.00 |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 12 | $673.92 |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $665.80 |
| 91320 | <1% | 13 | $655.50 | |
| 0052A | <1% | 14 | $642.18 | |
| 82947 | <1% | 234 | $607.51 | |
| 84480 | <1% | 59 | $561.31 | |
| 0111A | <1% | 12 | $550.44 | |
| 82105 | <1% | 39 | $529.89 | |
| 0074A | <1% | 12 | $513.53 | |
| 87081 | <1% | 105 | $501.72 | |
| 99442 | <1% | 207 | $496.14 | |
| 80055 | <1% | 12 | $479.71 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 477 | $459.62 |
| 0051A | <1% | 18 | $458.70 | |
| 82670 | <1% | 26 | $449.40 | |
| 90716 | <1% | 223 | $420.41 | |
| 73562 | <1% | 32 | $364.70 | |
| 82805 | <1% | 15 | $349.20 | |
| 99188 | <1% | 24 | $336.00 | |
| 85018 | <1% | 169 | $335.85 | |
| 83001 | <1% | 38 | $335.08 | |
| ATP18 | <1% | 63 | $329.10 | |
| 85007 | <1% | 178 | $314.01 | |
| 83525 | <1% | 44 | $312.90 | |
| 86038 | <1% | 42 | $286.52 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,567 | $271.86 |
| 84481 | <1% | 26 | $262.82 | |
| 86780 | <1% | 33 | $245.28 | |
| 90707 | <1% | 225 | $234.18 | |
| 87340 | <1% | 36 | $207.24 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 190 | $205.31 |
| 86376 | <1% | 24 | $199.05 | |
| 80299 | <1% | 14 | $192.78 | |
| 87449 | <1% | 28 | $185.98 | |
| Q3014 | Telehealth originating site facility fee | <1% | 57 | $151.50 |
| 0154A | <1% | 15 | $137.61 | |
| 90474 | <1% | 12 | $125.86 | |
| 93242 | <1% | 14 | $117.70 | |
| 96376 | <1% | 496 | $114.92 | |
| 82784 | <1% | 15 | $110.24 | |
| 80178 | <1% | 27 | $102.51 | |
| ATP07 | <1% | 16 | $101.16 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 1,000 | $88.02 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 237 | $87.58 |
| 87045 | <1% | 14 | $60.34 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 363 | $57.68 |
| 87177 | <1% | 12 | $56.84 | |
| 84550 | <1% | 87 | $50.50 | |
| 84100 | <1% | 1,004 | $40.70 | |
| 85730 | <1% | 13 | $37.10 | |
| 91300 | <1% | 5,155 | $35.94 | |
| G0008 | Administration of influenza virus vaccine | <1% | 268 | $31.25 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 95 | $30.94 |
| 86003 | <1% | 12 | $23.00 | |
| 84460 | <1% | 28 | $4.83 | |
| 82962 | <1% | 451 | $2.89 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 550 | $0.32 |
| 90680 | 0% | 1,202 | $0.00 | |
| 90744 | 0% | 350 | $0.00 | |
| 90698 | 0% | 870 | $0.00 | |
| 80320 | 0% | 92 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 683 | $0.00 |
| 91301 | 0% | 1,706 | $0.00 | |
| 90697 | 0% | 117 | $0.00 | |
| 90647 | 0% | 12 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 38 | $0.00 |
| 83615 | 0% | 12 | $0.00 | |
| 80069 | 0% | 33 | $0.00 | |
| 90723 | 0% | 30 | $0.00 | |
| 87468 | 0% | 56 | $0.00 | |
| 80329 | 0% | 14 | $0.00 | |
| 82550 | 0% | 14 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 15 | $0.00 |
| 90672 | 0% | 106 | $0.00 | |
| 80143 | 0% | 87 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 317 | $0.00 |
| 90648 | 0% | 149 | $0.00 | |
| 84145 | 0% | 15 | $0.00 | |
| 80179 | 0% | 29 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 20 | $0.00 |
| 90685 | 0% | 209 | $0.00 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 154 | $0.00 |
| 90700 | 0% | 26 | $0.00 | |
| 84450 | 0% | 13 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 13 | $0.00 |
| 90710 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCDERMOTT, VINCENT (SVP, CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Newton-Wellesley Hospital | Newton, MA | $36.31M |
| Mass General Brigham Medical Group, INC. | Salem, NH | $758K |
| Martha's Vineyard Hospital, INC. | Oak Bluffs, MA | $94K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.